Article citationsMore >>

Peipei Xu, Fan Wang, Chaoyang Guan, Jian Ouyang, Xiaoyan Shao, and Bing Chen. A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. Onco Targets Ther. 2016; 9: 5781-5789.

has been cited by the following article:

Article

Brentuximab for Refactory Hodgkin’s Lymphoma: A Case Report

1Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran

2Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran


American Journal of Cancer Prevention. 2017, Vol. 5 No. 3, 39-40
DOI: 10.12691/ajcp-5-3-4
Copyright © 2017 Science and Education Publishing

Cite this paper:
Edris Sadeghi, Mehrdad Payandeh. Brentuximab for Refactory Hodgkin’s Lymphoma: A Case Report. American Journal of Cancer Prevention. 2017; 5(3):39-40. doi: 10.12691/ajcp-5-3-4.

Correspondence to: Mehrdad  Payandeh, Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: md.payandeh@Yahoo.com

Abstract

Hodgkin's lymphoma (HL) continues to be an intriguing, and fascinating lymphoma [1]. HL is expected to cure the majority of patients. Brentuximab vedotin is a CD30 antibody. We survey efficacy of brentuximab in patient with HL who was resistant to treatment. A 43 year old male referred with cough and right supraclavicular lymphadenopathy. His disease was HL, nodular sclerosis type (stage IIB and grade II) with megakaryocytosis in bone marrow aspiration (BMB). He was treated with 6 cycles of induction chemotherapy including adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) and achieved a complete remission by imaging assessment. Then he received ifosfamide, carboplatin, etoposide (ICE) plus brentuximab vedotin (1.8 mg/kg every 3 weeks) regimen for 6 courses. At the end of this time he been eligible for autologous bone marrow transplantation (BMT). Bone marrow was done and after 13 days with good engraftment the patient discharge hospital. Therapists should be try with a specific target when they need a new and potent treatment like BMT for an active disease. Brentuximab vendotin is a new drug in policy of recurrence that it used for a few of cases in Iran.

Keywords